PeptideDB

Puromycin

CAS No.: 53-79-2

Puromycin (NSC-3055) is an antibiotic protein synthesis inhibitor. It inhibits protein synthesis by binding to RNA. It a
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Description Puromycin (NSC-3055) is an antibiotic protein synthesis inhibitor. It inhibits protein synthesis by binding to RNA. It also serves as an anticancer drug by suppressing the growth and metastasis in esophagus cancer cells by Akt phosphorylation. It is an antineoplastic and antitrypanosomal agent and is used in research as an inhibitor of protein synthesis.
Synonyms NSC 3055, NSC3055, Puromycine, 嘌呤霉素, NSC-3055
molecular weight 471.51
Molecular formula C22H29N7O5
CAS 53-79-2
Storage Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility DMSO: 100mg/mL (143.72mM)
References 1. Guo X, Duan Y, Ye X, Hu L, Xu T, Tong L, Yu M. Stable silencing of dll4 gene suppresses the growth and metastasis of esophagus cancer cells by attenuating Akt phosphorylation. Oncol Rep. 2018 May 8. doi: 10.3892/or.2018.6427. [Epub ahead of print] PubMed PMID: 29749499. 2. Yik-Sham Chung C, Timblin GA, Saijo K, Chang CJ. Versatile Histochemical Approach to Detection of Hydrogen Peroxide in Cells and Tissues Based on Puromycin Staining. J Am Chem Soc. 2018 May 3. doi: 10.1021/jacs.8b02279. [Epub ahead of print] PubMed PMID: 29722974. 3. Ahmad F, Salahuddin M, Alsamman K, Herzallah HK, Al-Otaibi ST. Neonatal maternal deprivation impairs localized de novo activity-induced protein translation at the synapse in the rat hippocampus. Biosci Rep. 2018 Apr 26. pii: BSR20180118. doi: 10.1042/BSR20180118. [Epub ahead of print] PubMed PMID: 29700212. 4. Argüello RJ, Simoes MR, Mendes A, Camosseto V, Torres AG, de Pouplana LR, van de Pavert SA, Gatti E, Pierre P. SunRiSE: measuring translation elongation at single cell resolution by flow cytometry. J Cell Sci. 2018 Apr 26. pii: jcs.214346. doi: 10.1242/jcs.214346. [Epub ahead of print] PubMed PMID: 29700204. 5. Han W, Zhang C, Shi C, et al. Roles of eIF3m in the tumorigenesis of triple negative breast cancer[J]. Cancer Cell International. 2020, 20: 1-16